Izmir Biomedicine and Genome Center, Dokuz Eylul University Health Campus Balcova, Izmir, Turkey.
Izmir Biomedicine and Genome Center, Dokuz Eylul University Health Campus Balcova, Izmir, Turkey; Izmir International Biomedicine and Genome Institute (iBG-Izmir), Dokuz Eylul University Health Campus, Balcova, Izmir, Turkey.
Adv Protein Chem Struct Biol. 2020;119:247-308. doi: 10.1016/bs.apcsb.2019.08.007. Epub 2019 Nov 26.
Multiple sclerosis (MS) is a chronic, autoimmune and neuroinflammatory disease of the central nervous system (CNS) mediated by autoreactive T cells directed against myelin antigens. Although the crucial role of adaptive immunity is well established in MS, the contribution of innate immunity has only recently been appreciated. Microglia are the main innate immune cells of the CNS. Similar to other myeloid cells, microglia recognize both exogenous and host-derived endogenous danger signals through pattern recognition receptors (PRRs) localized on their cell surface such as Toll Like receptor 4, or in the cytosol such as NLRP3. The second one is the sensor protein of the multi-molecular NLRP3 inflammasome complex in activated microglia that promotes the maturation and secretion of proinflammatory cytokines, interleukin-1β and interleukin-18. Overactivation of microglia and aberrant activation of the NLRP3 inflammasome have been implicated in the pathogenesis of MS. Indeed, experimental data, together with post-mortem and clinical studies have revealed an increased expression of NLRP3 inflammasome complex elements in microglia and other immune cells. In this review, we focus on microglial NLRP3 inflammasome activation in MS. First, we overview the basic knowledge about MS, microglia and the NLRP3 inflammasome. Then, we summarize studies about microglial NLRP3 inflammasome activation in MS and its animal models. We also highlight experimental therapeutic approaches that target different steps of NLRP inflammasome activation. Finally, we discuss future research avenues and new methods in this rapidly evolving area.
多发性硬化症(MS)是一种中枢神经系统(CNS)的慢性、自身免疫性和神经炎症性疾病,由针对髓鞘抗原的自身反应性 T 细胞介导。尽管适应性免疫的关键作用在 MS 中已得到充分证实,但先天免疫的贡献最近才得到重视。小胶质细胞是中枢神经系统的主要先天免疫细胞。与其他髓样细胞类似,小胶质细胞通过位于其细胞表面的模式识别受体(PRRs)识别外源性和宿主来源的内源性危险信号,例如 Toll 样受体 4,或在细胞质中识别,例如 NLRP3。后者是激活的小胶质细胞中多分子 NLRP3 炎性小体复合物的传感器蛋白,可促进促炎细胞因子白细胞介素-1β和白细胞介素-18 的成熟和分泌。小胶质细胞的过度激活和 NLRP3 炎性小体的异常激活与 MS 的发病机制有关。事实上,实验数据以及死后和临床研究都揭示了 MS 中小胶质细胞和其他免疫细胞中 NLRP3 炎性小体复合物元素的表达增加。在这篇综述中,我们重点关注 MS 中小胶质细胞 NLRP3 炎性小体的激活。首先,我们概述了关于 MS、小胶质细胞和 NLRP3 炎性小体的基本知识。然后,我们总结了有关 MS 中小胶质细胞 NLRP3 炎性小体激活及其动物模型的研究。我们还强调了针对 NLRP 炎性小体激活不同步骤的实验治疗方法。最后,我们讨论了这个快速发展领域的未来研究方向和新方法。